首页> 外文期刊>British journal of clinical pharmacology >Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy
【24h】

Risk of acute and serious liver injury associated to nimesulide and other NSAIDs: data from drug‐induced liver injury case–control study in Italy

机译:与尼美舒利和其他非甾体抗炎药相关的急性和严重肝损伤的风险:来自意大利药物性肝损伤病例对照研究的数据

获取原文
           

摘要

Aim Drug-induced liver injury is one of the most serious adverse drug reactions and the most frequent reason for restriction of indications or withdrawal of drugs. Some nonsteroidal anti-inflammatory drugs (NSAIDs) were withdrawn from the market because of serious hepatotoxicity. We estimated the risk of acute and serious liver injury associated with the use of nimesulide and other NSAIDs, with a prevalence of use greater than or equal to 5%. Methods This is a multicentre case–control study carried out in nine Italian hospitals from October 2010 to January 2014. Cases were adults, with a diagnosis of acute liver injury. Controls presented acute clinical disorders not related to chronic conditions, not involving the liver. Adjusted odds ratio (ORs) with 95% confidence interval (CI) were calculated initially with a bivariate and then multivariate analysis. Results We included 179 cases matched to 1770 controls. Adjusted OR for acute serious liver injury associated with all NSAIDs was 1.69, 95% CI 1.21–2.37. Thirty cases were exposed to nimesulide (adjusted OR 2.10, 95% CI 1.28–3.47); the risk increased according to the length of exposure (OR > 30?days: 12.55, 95% CI 1.73–90.88) and to higher doses (OR 10.69, 95% CI 4.02–28.44). Risk of hepatotoxicity was increased also for ibuprofen, used both at recommended dosages (OR 1.92, 95% CI 1.13–3.26) and at higher doses (OR 3.73, 95% CI 1.11–12.46) and for ketoprofen ≥ 150?mg (OR 4.65, 95% CI 1.33–10.00). Conclusion Among all NSAIDs, nimesulide is associated with the higher risk, ibuprofen and high doses of ketoprofen are also associated with a modestly increased risk of hepatotoxicity.
机译:目的药物引起的肝损伤是最严重的药物不良反应之一,也是限制适应症或停药的最常见原因。由于严重的肝毒性,一些非甾体类抗炎药(NSAIDs)被撤出市场。我们估计使用尼美舒利和其他NSAID会导致急性和严重肝损伤的风险,且使用率大于或等于5%。方法这是一项从2010年10月至2014年1月在意大利9家医院进行的多中心病例对照研究。病例均为成年人,诊断为急性肝损伤。对照表现出与慢性病无关的急性临床疾病,不涉及肝脏。首先使用二元分析,然后进行多变量分析,计算出具有95%置信区间(CI)的调整后优势比(OR)。结果我们纳入了179例与1770例对照匹配的病例。与所有NSAIDs相关的急性严重肝损伤的校正OR为1.69,95%CI 1.21-2.37。 30例暴露于尼美舒利(校正后OR 2.10,95%CI 1.28–3.47);根据暴露时间的长短(OR> 30天:12.55,95%CI 1.73–90.88)和更高的剂量(OR 10.69,95%CI 4.02–28.44),风险增加。布洛芬,建议剂量(OR 1.92,95%CI 1.13–3.26)和更高剂量(OR 3.73,95%CI 1.11–12.46)使用和酮洛芬≥150?mg(OR 4.65)的肝毒性风险也增加。 ,95%CI 1.33–10.00)。结论在所有非甾体抗炎药中,尼美舒利与较高的风险相关,布洛芬和高剂量的酮洛芬也与适度增加的肝毒性风险相关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号